Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.539, 2007-01, pp. : 5-5
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Erlotinib + gemcitabine of no value in pancreatic cancer
Inpharma, Vol. 1, Iss. 1610, 2007-01 ,pp. :
Access to resources
Recommend
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
By El-Rayes Bassel Philip Philip Sarkar Fazlul Shields Anthony Ferris Ann Hess Kenneth Kaseb Ahmad Javle Milind Varadhachary Gauri Wolff Robert Abbruzzese James
Investigational New Drugs, Vol. 29, Iss. 4, 2011-08 ,pp. :
Gemcitabine of no benefit after pancreatic cancer resection
Inpharma, Vol. 1, Iss. 1628, 2008-01 ,pp. :
UK NICE guidance on gemcitabine for pancreatic cancer
Inpharma, Vol. 1, Iss. 1289, 2001-01 ,pp. :
PEFG superior to gemcitabine for advanced pancreatic cancer
Inpharma, Vol. 1, Iss. 1499, 2005-01 ,pp. :